ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Merus NV

Merus NV (2GH)

41.40
0.00
( 0.00% )
Updated: 10:32:49
Realtime Data

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
41.40
Bid
41.60
Ask
42.20
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus annonce sa participation aux prochaines journées Investisseurs

Merus annonce sa participation aux prochaines journées Investisseurs UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 07 nov. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.8-4.1666666666743.2474319244.19451697DE
4-8.6-17.25051.540.411744.74603537DE
12-3.8-8.4070796460245.251.540.412747.17167127DE
26-6.8-14.107883817448.257.540.415948.57608533DE
5218.4802358.521.39999917344.34418355DE
15617.673.949579831923.858.51916742.00023485DE
26017.673.949579831923.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0608 €
(69.83%)
1.41M
A6NAsana Inc
20.20 €
(38.36%)
5.14k
C62Chariot Limited
0.031 €
(29.17%)
3.5k
NL8Genesis Ai Corp
0.0194 €
(27.63%)
6.83k
EJ7Energy Resources of Australia
0.0025 €
(25.00%)
188.5k
AXIAtos SE
0.0031 €
(-98.43%)
1.15B
M0YNMynaric AG
1.23 €
(-75.98%)
72.92k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0031 €
(-98.43%)
1.15B
D7GNel ASA
0.2629 €
(-1.54%)
3.65M
TUI1Tui AG
8.47 €
(1.95%)
1.96M
TE9Teco 2030 ASA
0.0608 €
(69.83%)
1.41M
LHADeutsche Lufthansa AG
6.68 €
(1.71%)
1.08M

Discussion

View Full Feed
jbsliverer jbsliverer 23 seconds ago
Trump assembling US cabinet of billionaires worth combined $340bn
https://www.theguardian.com/us-news/2024/dec/06/trump-us-cabinet-billionaires
President-elect tapping mega-rich backers for positions that will give them power to cut spending on public services


Cu
koolmc koolmc 25 seconds ago
yep if they do follow through can hit the .008-.009 area again
BCDS
trader_ron trader_ron 27 seconds ago
000's Play for 2025 -  style="caret-color: rgb(0, 0, 0); color: rgba(0, 0, 0, 1); font-family: UICTFontTextStyleBody; font-size: 17px"$PPJE - How a legacy of experience and knowledge grew into the medical billing service of the future.
Over the past two-and-a-half decades. Professional
PPJE
shurtha2000 shurtha2000 28 seconds ago
.75 to $1 by Trumps Inaugeration
NAK
gp22 gp22 32 seconds ago
Here is the Israel version of $PDYN, except they have MULTIPLE Nasdaq companies that they currently partner with....AI Software leader $MTEK partners with Nasdaq companies $LPTH, $MOB, $FRZO and others that require privacy clause in deals. ... $MTEK unknown & the last AI Drone/AI Software play to
FRZO LPTH MOB
TrendTrade2016 TrendTrade2016 47 seconds ago
QBTS MONSTER
QBTS
SHEEPWOLF SHEEPWOLF 1 minute ago
$ILLR: TikTok’s Chinese parent company faces a ban in the US if it doesn’t meet a Jan. 19 deadline to sell the video-sharing app as a result of a federal appeals court ruling https://www.bloomberg.com/news/articles/2024-12-06/tiktok-faces-us-ban-after-appeals-court-refuses-to-block-law?utm_source=we
ILLR
pennyonfire pennyonfire 1 minute ago
Watching for break here.
GRLT
Torez Torez 1 minute ago
Shouldn't this be at $1 at this point lol ? This pos cant even lose zero for past 3 years. So keep buying those cheapies lol
SHIBUSD
PonderosaPack PonderosaPack 1 minute ago
LOL - One 40 Burger coming up. The elves are slathering on the mayo now. don't hold the pickles.
IONQ
trader_ron trader_ron 2 minutes ago
Great time to load a 000's in the Healthcare space, Fully Reporting to go with it, B&H for the run. 
PPJE
ChannelTrader ChannelTrader 2 minutes ago
I was alerted on BTC @ .25 very early on but passed it up.
nelson1234 nelson1234 2 minutes ago
Gil, re FEIM hasn't the 'satellite sector' become very hot recently? I thought I saw some posts here re a bunch of small-cap satellite plays that were being bought not so much for 'fundamentals' but more for just being in the sector. But maybe I got that wrong.
manibiotech manibiotech 2 minutes ago
You forgot to multiply that by 4
NWBO
chemist72 chemist72 2 minutes ago
Big move won't come until next year when MJ rescheduling case is decided in court.

Until then it is either a flip trade or a buy and hold. imo
ILST
Konaploinks Konaploinks 2 minutes ago
New 52 week high!! 37.705
IONQ
peteypickem peteypickem 2 minutes ago
ILST,,,, wayyyyyyyyyyyyyyyyyyyyyyyy higher
ILST
SHEEPWOLF SHEEPWOLF 2 minutes ago
$ILLR: TikTok’s Chinese parent company faces a ban in the US if it doesn’t meet a Jan. 19 deadline to sell the video-sharing app as a result of a federal appeals court ruling https://www.bloomberg.com/news/articles/2024-12-06/tiktok-faces-us-ban-after-appeals-court-refuses-to-block-law?utm_source=we
ILLR
Graniteguy Graniteguy 2 minutes ago
Grossly incorrect. There was ZERO pumping in that "Fire side" chat and if anything Missling doesn't do enough pumping and publicity regarding Anavex's trial results in my opinion. Anavex, nor Blarcamesine is not exactly a household name...yet. CEO Missling's best known fault is predicting over optim
AVXL
koolmc koolmc 2 minutes ago
yep see that lol, probably sold to chase something else.
ASII
jimr1717 jimr1717 2 minutes ago
Newbies DD Updated 🏆️ >>, Marc Walther was found liable in a securities fraud lawsuit...

Complaint:
https://drive.google.com/file/d/1Wpk0lRCJaTOI3dmR_BeSNw6eWtnTt71s/view

Judgement: $397,744.50
https://drive.google.com/file/d/1nZjmmsmCwJlFwm9TR6Nvo
HGYN HYGN
justhefax justhefax 2 minutes ago
Yes I did see this last night, and thanks for sharing here.

It is rather stunning. The LLC generated all the earnings represented in the last Q.

So the company GAVE AWAY its namesake Kona Hemp brand, and now Covert. That leaves a shell.

Does the INC reta
KGKG
The_Gman The_Gman 2 minutes ago
World’s 1st XNO-powered EV charges 100% in 10 mins in niobium battery breakthrough

https://www.yahoo.com/news/world-1st-xno-powered-ev-175251651.html
NB

Your Recent History

Delayed Upgrade Clock